Biosimilars could save the healthcare system billions


Cost Plus Drug Company CEO Mark Cuban recently pointed out that self-insured businesses could save over $70,000 per employee annually by getting their workers to switch from AbbVie’s blockbuster anti-inflammatory treatment Humira to a lower-cost biosimilar called Yusimry.

Humira has a list price of roughly $7,000 per month. Since it lost market exclusivity last year, nine nearly identical copycats have hit pharmacy shelves. A year’s supply of Yusimry costs the same as just one month of Humira.

Why doesn’t every employer in America follow Cuban’s advice? The answer has three letters: PBM.

Click to read the full article in the Washington Examiner.

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top